


thereof, in combination with a pharmaceutically acceptable carrier, wherein the bicyclic aromatic compound has the structural formula of claim 65.

69. A pharmaceutical composition for control of cellular processes regulated by retinoid compounds, Vitamin D, or thyroid hormone, comprising an effective regulating amount of a bicyclic aromatic compound, or a pharmaceutically acceptable ester, amide or salt thereof, in combination with a pharmaceutically acceptable carrier, wherein the bicyclic aromatic compound has the structural formula of claim 66.

70. A compound having the structural formula



REMARKS

Please bill Deposit Account 12-2475 for any fees required by the present filing.

In accordance with 37 CFR §1.607(c), Applicants hereby inform the Examiner that claims 64-70, newly added in the present amendment contain subject matter that overlaps with claims in United States Patent No. 5,466,861 ("the '861 Patent") issued to Dawson, et al., on November 14, 1995 (included herewith as Exhibit A) and U.S. Patent No. 5,837,725 ("the '725 Patent") also issued to Dawson, et al., on November 17, 1998 (included herewith as Exhibit B). Applicants believe both patents have been assigned to

SRI International of Menlo Park, California and the La Jolla Cancer Research Foundation of La Jolla, California. This amendment is submitted to present new claims for the purpose of provoking an interference with the '861 and '725 Patents.

At least claims 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23 of the '861 Patent include subject matter that overlaps with claims 64 and 67 in the '496 Application.

At least claims 1, 2, 3, 4, 6, 7, 12, 15 and 23 of the '861 Patent include subject matter that overlaps with claims 65 and 68 in the '496 Application.

At least claims 1, 2, 3, 4, 5, 6, 7, 8, 15, and 23 of the '861 Patent include subject matter that overlaps with claims 66 and 69 in the '496 Application.

Claim 13 of the '861 Patent corresponds to claims 70 in the '496 Application.

At least claims 1, 2, 3, 4, 5, 7, 10, 11, 12, 13, 14, 15, 26, 27, 28 and 29 of the '725 Patent include subject matter that overlaps with claims 64 and 67 in the '496 Application.

At least claims 1, 2, 3, 5, 7, 10, 11, 13, 14, 26, 27, 28 and 29 of the '725 Patent include subject matter that overlaps with claims 65 and 68 in the '496 Application.

At least claims 1, 2, 3, 5, 7, 10, 11, 12, 13, 14, 15, 26, 27, 28 and 29 of the '725 Patent include subject matter that overlaps with claims 66 and 69 in the '496 Application.

The '861 Patent issued on U.S. Application No. 07/982,305, filed November 25, 1992. The claims in the '861 Patent relate to bridged aromatic compounds and pharmaceutical compositions including an effective amount of the bridged aromatic compounds.

The '725 Patent issued on U.S. Application No. 08/448,991, filed May 24, 1995, which was a divisional of U.S. Application No. 07/982,305, filed November 25, 1992 (now the '861 Patent). The claims in the '725 Patent relate to bridged aromatic compounds and pharmaceutical compositions including an effective amount of the bridged aromatic compounds.

The '496 Application, filed October 22, 1993, is a continuation-in-part of Application Serial No. 08/052,051, filed April 21, 1993 (now abandoned), which is a continuation-in-part of Application Serial No. 08/027,747, filed March 5, 1993 (now abandoned), which is a continuation-in-part of Application Serial No. 08/003,223, filed January 11, 1993 (now abandoned), which is a continuation-in-part of Application Serial No. 07/944,783, filed September 11, 1992 (now abandoned), which is a continuation-in-part of Application Serial No. 07/872,707, filed April 22, 1992 (now abandoned). Applicants therefore enjoy an earlier effective filing date than the '861 and '725 Patents, whose earliest possible effective filing date would be November 25, 1992. Accordingly, the requirements of 37 C.F.R. 1.608(a) and (b) are inapplicable here.

It is respectfully submitted that the newly proposed claims are patentable, both over the prior art identified by Applicants and over the art identified in the prosecution of the '861 and '725 Patents.

Patent No.
203/268


Support for the claims in the '496 Application, presented in a table format, is
submitted herewith as Exhibit E.

Respectfully submitted,

LYON & LYON LLP

Dated: August 10, 1999

By


Michael J. Wise
Registration No. 34,047

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600